Kong MW, Sun FD, Pei ZY, Xu L, Wang ZB, Chen Y, Tang SQ, Yang TF, He GX. Cardiotoxicity induced by fluoropyrimidine drugs in the treatment of gastrointestinal tumors. World J Gastrointest Oncol 2024; 16(2): 251-254 [PMID: 38425398 DOI: 10.4251/wjgo.v16.i2.251]
Corresponding Author of This Article
Ting-Fang Yang, MD, Doctor, Department of Oncology, Guiqian International General Hospital, No. 1 Dongfeng Avenue, Wudang, Guiyang 550018, Guizhou Province, China. 672539517@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 251-254 Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.251
Cardiotoxicity induced by fluoropyrimidine drugs in the treatment of gastrointestinal tumors
Mo-Wei Kong, Feng-Di Sun, Zhen-Ying Pei, Li Xu, Ze-Bi Wang, Yan Chen, Shu-Qing Tang, Ting-Fang Yang, Guo-Xiang He
Mo-Wei Kong, Feng-Di Sun, Zhen-Ying Pei, Li Xu, Ze-Bi Wang, Yan Chen, Shu-Qing Tang, Guo-Xiang He, Department of Cardiology, Guiqian International General Hospital, Guiyang 550018, Guizhou Province, China
Ting-Fang Yang, Department of Oncology, Guiqian International General Hospital, Guiyang 550018, Guizhou Province, China
Author contributions: He GX and Yang TF provided crucial suggestions and guidance for the writing; Kong MW wrote the manuscript; Chen Y, Sun FD, Pei ZY, Wang ZB and Tang SQ reviewed and revised the manuscript; all authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ting-Fang Yang, MD, Doctor, Department of Oncology, Guiqian International General Hospital, No. 1 Dongfeng Avenue, Wudang, Guiyang 550018, Guizhou Province, China. 672539517@qq.com
Received: September 23, 2023 Peer-review started: September 23, 2023 First decision: December 26, 2023 Revised: December 28, 2023 Accepted: January 19, 2024 Article in press: January 19, 2024 Published online: February 15, 2024 Processing time: 131 Days and 20 Hours
Abstract
In this editorial, we review the article published in World J Gastrointest Oncol 2019, 11: 1031-1042. We specifically focus on the occurrence, clinical characteristics, and risk factors of fluoropyrimidine drug-related cardiotoxicity in patients with gastrointestinal tumors. Despite significant advancements in diagnostic and therapeutic techniques that have reduced mortality rates associated with digestive system tumors, the incidence and mortality rates of treatment-related cardiotoxicity have been increasing, severely impacting the survival and prognosis of cancer patients. Fluoropyrimidine drugs are widely used as antimetabolites in the treatment of malignant tumors, including gastrointestinal tumors, and they represent the second largest class of drugs associated with cardiotoxicity. However, there is often a lack of awareness or understanding regarding their cardiotoxic effects and associated risks.
Core Tip: This editorial focuses on the occurrence, clinical characteristics, and risk factors of fluoropyrimidine drug-related cardiotoxicity in patients with gastrointestinal tumors. Despite advancements in diagnostic and therapeutic techniques for digestive system tumors, treatment-related cardiotoxicity rates have been increasing, impacting the survival and prognosis of cancer patients. Fluoropyrimidine drugs, widely used in treating malignant tumors, including gastrointestinal tumors, are the second largest class of drugs associated with cardiotoxicity. However, there is often a lack of awareness or understanding regarding their cardiotoxic effects and associated risks.